MSPLIT-DIA: sensitive peptide identification for data-independent acquisition
To the Editor: Recently developed data-independent acquisition (DIA) approaches for mass spectrometry data collection are gaining traction in the proteomics field. We present MSPLIT-DIA (mixturespectrum partitioning using libraries of identified tandem mass spectra) as a spectral-matching tool for untargeted and sensitive peptide identification in DIA data (http://proteomics.ucsd.edu and Supplementary Software).
Despite the sensitivity of data-dependent acquisition (DDA) on modern mass spectrometers, its semistochastic nature leads to sampling of a different subset of peptides each time a sample is analyzed, resulting in missing peptide identifications and decreased reproducibility across multiple runs. DIA strategies aim to alleviate this problem by systematically isolating and fragmenting ions on the basis of only their m/z, and not their intensity. DIA strategies often segment the usable m/z range into wide isolation windows (for example, 25-Da windows in SWATH 1 ), generating complex spectra with multiple peptides that cannot be readily identified with DDA tools. Instead, DIA data-analysis tools are based mostly on targeted extraction of quantitative information via selected reaction monitoringinspired strategies 1 , although recent reports published in Nature Methods 2,3 , one of which 3 was under review concurrently with this Correspondence, demonstrate the extraction of pseudo-MS/MS spectra, which are then searched with DDA database search tools. Nevertheless, computational tools that explore alternative strategies for identifying peptides in multiplex spectra are still needed.
We introduce MSPLIT-DIA, a spectral-matching tool for untargeted peptide identification in DIA data ( Fig. 1a and Supplementary Note  1) . Because it is likely that each multiplexed spectrum will contain many peaks from coeluting peptides, MSPLIT-DIA uses spectrum projections to match library spectra to each DIA spectrum, after were identified by DIA-Umpire (Supplementary Fig. 6 and Supplementary Tables 1 and 2 ). Nearly 70% of the additional peptides identified by Group-DIA were multiple hits ( Supplementary  Fig. 7) . A comparison of peptide intensities suggested that Group-DIA was more efficient in identifying low-abundance peptides (Fig.  1c) . We manually checked the XICs of all SIS peptides identified by Group-DIA (but not DIA-Umpire) and confirmed that they were true positives (Supplementary Figs. 8-10 and Supplementary Data).
To prove the validity of the decoy spectra, we investigated their properties. Product-ion intensities of target and decoy spectra had similar distributions (Supplementary Fig. 11 ). Decoy spectra were mapped to target and decoy databases with similarly low confidence (Supplementary Fig. 12 ). Additionally, receiver operating characteristic plots suggested that target spectra could be distinguished from decoy spectra when they were mapped to the target database (Supplementary Fig. 13 ). These results suggested that decoy spectra could be used for error estimation in the generation of pseudospectra.
We also compared the quantification accuracy of Group-DIA with that of OpenSWATH 6 , a targeted analysis strategy. SIS peptide intensities suggested that the two tools had similar quantification accuracy (Supplementary Fig. 14) . However, Group-DIA obtained more consistent quantification data in replicates than OpenSWATH did (Supplementary Fig. 15 ).
We then evaluated the performance of Group-DIA in analyzing immunoprecipitation (IP) samples. We immunoprecipitated TNFR1 (tumor necrosis factor receptor 1) complex from L929 cells treated with TNF for six different time periods and analyzed these IP samples using shotgun MS to build a spectral library for OpenSWATH analysis and SWATH-MS for generating DIA files. Group-DIA identified more peptides than DIA-Umpire did ( Supplementary  Fig. 16 and Supplementary Table 3 ). The majority of the peptides identified by these two workflows can be found in the spectral library ( Supplementary Fig. 17 , Supplementary Table 4 and Supplementary Data). Temporal profiles of the proteins revealed by Group-DIA, DIA-Umpire and OpenSWATH are shown in Figure 1d and Supplementary Table 5 . Comparison of the quantifications of replicates showed that Group-DIA was more consistent than OpenSWATH (Supplementary Fig. 18 ).
Group-DIA, DIA-Umpire and OpenSWATH revealed 7, 17 and 15 proteins, respectively, whose levels increased time-dependently in TNF IP (Fig. 1d) . We performed a manual check, which showed that Group-DIA could identify more truly regulated proteins with less background noise than the other approaches could (Fig. 1d and Supplementary Table 5) .
Finally, we compared the performance of Group-DIA with that of OpenSWATH in an analysis of SWATH-MS data from wholecell lysates (Supplementary Note 3, Supplementary Methods,  Supplementary Figs. 19-21, Supplementary Tables 6-9 and Supplementary Data). We concluded that the two methods are essentially equivalent for analyzing DIA data from highly complex samples. About half of the hits obtained with both methods were false positives and needed to be removed via a manual check.
Group-DIA source code and documentation are available as Supplementary Software and at http://yuanyueli.github.io/ group-dia/. Figs. 6 and 7) . Unlike DDA dynamic-exclusion protocols, MSPLIT-DIA used in an untargeted manner yields spectral counts (Fig. 1d ) that are not biased by precursor-ion selection, and we used these as a rough measure of abundance. The substantial gains (~3-4×) in spectral counts synergized with the reproducibility improvements to yield better signal-to-noise ratios for approaches relying on spectral counts, such as SAINT 7 . For MEPCE and EIF4A2, this resulted in the confident detection of ~33% more interacting proteins (Fig. 1e ) that were consistent with the biological function of the bait proteins (Supplementary Tables 1 and 2 and Supplementary  Fig. 7) . Thus, even when MSPLIT-DIA is coupled only to rough abundance measurements, the sensitivity, reproducibility and spectral counts obtained with this method improve the sensitivity of detection of interactions. The generic SWATHAtlas library 5 was even better at detecting interactors than the sample-specific library was (Supplementary Figs. 6 and 7 ; it was also more sensitive than which spectrum-spectrum match (SSM) similarity can be evaluated using the normalized dot product. Because peptides are acquired and analyzed throughout their elution profiles, MSPLIT-DIA also evaluates the similarity of the matched peaks between library spectra and multiplexed spectra across multiple consecutive DIA spectra. Finally, the statistical significance of SSMs is assessed at a 1% peptidelevel false discovery rate (FDR) using the target-decoy approach. For each multiplexed spectrum, all SSMs with FDR ≤ 1% are returned as matches. MSPLIT-DIA effectively identified up to ten peptides per spectrum, with complex samples such as human lysate generating a predominance of spectra containing more than one peptide (Fig. 1b  and Supplementary Fig. 1) .
Because DDA is the current standard for sensitive peptide identification, we compared MSPLIT-DIA with MSGFDB 4 analysis of DDA data (Fig. 1c and Supplementary Figs. 2-4) . Although the performance of the two methods was similar when we used spectral libraries generated from the same samples, MSPLIT-DIA with the SWATHAtlas 5 spectral library identified 26-31% more human peptides than the corresponding DDA analysis did. MSPLIT-DIA also identified 66-89% more human peptides than DIA-Umpire 2 and 81-88% and 86-107% more than PeakView 6 and Skyline, respectively, in the same DIA runs. MSPLIT-DIA further enabled much more reproducible observations across four runs than DDA did (Supplementary Fig. 5 ; 70% versus 50% at 1% FDR). The reproducibility gains were most pronounced for the 60% lower-abundance human peptides ( Fig.  1d and Supplementary Fig. 5 ; 59% gains). This is important for comparative studies, in which biological conclusions are drawn from the detection and nondetection of lowto medium-abundance peptides and proteins across samples.
We benchmarked MSPLIT-DIA for the analysis of protein-protein interactions (a major application of comparative proteomics) by reanalyzing DDA and DIA data for biological triplicates of the Table 3 presents a description of the samples used in this study). (c) The number of unique peptides identified in a human lysate analyzed by itself (left) and with a spiked-in standard 48-protein mixture (UPS1; right) using six different dataanalysis approaches. MSPLIT-DIA was carried out either with a library from paired DDA runs of the same sample (green) or using the large generic SWATHAtlas library (purple); representative samples shown. (d) Number of peptides detected across four runs (top) and reproducibility analysis comparing MSPLIT-DIA and MSGFDB-DDA (bottom) with regard to peptide abundance (x-axis); four samples were used per condition. (e) Comparison of MSGFDB-DDA and MSPLIT-DIA as applied in a semiquantitative approach to detect protein-protein interactions in affinity-purified samples from two bait proteins (EIF4A2 and MEPCE) and a negative control (GFP); biological triplicates were used per condition. (f) DIA workflow using MSPLIT-DIA eliminates the need for additional DDA runs, spike-in peptides or manual curation for the generation of sample-specific assay libraries. (g) Results of PeakView and MSPLIT-DIA peptide quantification with and without RT alignment and with and without an MSPLIT-generated assay library; biological triplicates were used per condition. Multiplexed spectrum Nonlinearity is a general problem for factorial ANOVA for several types of variables. This can be dealt with in many cases by the use of pilot studies to establish the linear-response range. However, this is often not possible in drug studies, where random effects can cause minor but significant shifts in response curves between experiments, such that the linearity assumption cannot be made. To overcome this, it is best to study drug interactions in experiments that generate response curves for the drugs both individually and in combination in the same experimental replicate. Data from these types of experiments can be used in a variety of appropriate analyses such as isobologram and combination index 2 , curve shift 3 and nonlinear mixed effect 4 analyses. An additional advantage of these methods is that they allow for quantification of the strength of the interaction between drugs, which is crucial for practical decision making in drug combination experimental design.
It is important for researchers to be aware of the pitfalls of factorial experimental designs in the study of drug combination. There is a large and growing literature on the interpretation of degrees of drug synergy (positive interaction) using these methods [2] [3] [4] [5] . Recent advances include the application of nonparametric methods as well as more precise consideration of the specific nonlinear forms of response curves and the relative potency of the two drugs being investigated 6 . Now that computationally intense methods are available to all with access to a personal computer, there is no reason not to use more robust and informative methods.
